The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
http://www.synairgen.com/documents/PressreleaseH5N1final.pdf
Drug developer Synairgen thinks that it may have the answer to problems faced by victims of asthma and COPD (chronic obstructive pulmonary disease, often known as smokers’ cough). They can find it especially hard to fight off the common cold or similar flu-like viruses, often ending up in hospital. Synairgen believes that they suffer from a deficiency of the interferon-β protein and that the delivery of the latter can boost the fighting qualities of the lungs. Now conducting a Phase II trial for asthmatics, Synairgen has recruited patients and expects to complete the study by the autumn. Some preliminary statistical evidence could become available in the second quarter, and if the results are good then Synairgen should have something of real value. Beyond that Synairgen is planning a trial for COPD sufferers, but the most exciting prospect of all is that interferon-β could prove effective against all manner of winter viruses. Drug developers are very high risk, but Synairgen promises that 2011 will be a ‘transformational year.’ If this transformation is in the right direction, then the shares could fly.
and (sng)
take a look at (zox) (lpx) (abh) but dyor
one to look at zincox ( zox ) a little gem in the making imho but as usual dyor
sp 19.20
huge potential here but dyor
huge potential here but dyor
Respiratory drug discoverer Synairgen has hired Deloittes to handle interest from major pharmaceutical groups in its potential Interferon Beta-based flu and asthma treatments. The company's decision to use the accounting and financial advice group follows successful tests earlier this year showing dramatic falls in influenza re-infection rates in patients treated with an Inteferon Beta-based product compared with untreated patients. Based at Southampton General Hospital, AIM-quoted Synairgen, which was founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, has been encouraged by its testing of inhaled Interferon-Beta to treat or prevent viral exacerbation of asthma, COPD (chronic obstructive pulmonary diseases such as chronic bronchitis, emphysema and smokers' complaints). A Phase I clinical trial study, to prove safety, was completed earlier this month, clearing the way for a move to Phase II, for 'proof of concept'. Then came a new breakthrough in the spring, with data from Synairgen's new laboratory infection model indicating SNG001, the company's inhaled Interferon-Beta product, could prevent the spread of influenza between cells even after the illness had taken hold. Interferon-Beta already provides long-established treatments for multiple sclerosis and other illnesses, but Synairgen has obtained patents in the USA and Europe for its application to flu, asthma and COPD. Chief executive officer Richard Marsden, an experienced sector player, expects pre-clinical trial flu work to start in the fourth quarter of this year, with the COPD application entering Phase II in 2011. He says Synairgen, which lost £2.6m in the year to June but still has £5m in the bank, can fund itself to the end of next year. Floated at 130p in 2005, Synairgen shares have been dire performers, falling at one stage to 13p, rallying to 58p and now back down to 24.5p. But, if the indications so far for asthma, COPD and flu are borne out and 'big pharma' starts to nibble, they could well repay a bold flutter.
http://www.synairgen.com/documents/USRhinoviruspatent191010Final.pdf
does anyone have info about possible TO by 2K ?
nice rise
i'm i the only one holding this share?????
to celebrate on this one today?and what about VIY?